← Back to Screener
Roivant Sciences Ltd. Common Shares (ROIV)
Price$29.08
Favorite Metrics
Price vs S&P 500 (26W)77.23%
Price vs S&P 500 (4W)-1.80%
Market Capitalization$21.35B
All Metrics
Book Value / Share (Quarterly)$6.02
P/TBV (Annual)1.44x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-19.30%
Cash Flow / Share (Quarterly)$-1.08
Price vs S&P 500 (YTD)33.33%
Gross Margin (TTM)91.21%
Net Profit Margin (TTM)-6079.94%
EPS (TTM)$-1.17
10-Day Avg Trading Volume4.31M
EPS Excl Extra (TTM)$-1.17
Revenue Growth (5Y)-15.56%
EPS (Annual)$-0.24
ROI (Annual)-3.67%
Gross Margin (Annual)96.86%
Net Profit Margin (5Y Avg)-736.52%
Cash / Share (Quarterly)$6.38
Revenue Growth QoQ (YoY)-77.83%
ROA (Last FY)-3.16%
Revenue Growth TTM (YoY)-86.36%
EBITD / Share (TTM)$-1.81
ROE (5Y Avg)-22.80%
Operating Margin (TTM)-9107.18%
Cash Flow / Share (Annual)$-1.21
P/B Ratio5.00x
P/B Ratio (Quarterly)3.54x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1492.94x
Net Interest Coverage (TTM)-72.78x
ROA (TTM)-15.59%
EV / EBITDA (TTM)4.54x
EPS Incl Extra (Annual)$-0.24
Current Ratio (Annual)33.47x
Quick Ratio (Quarterly)30.66x
3-Month Avg Trading Volume6.57M
52-Week Price Return197.70%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.17
P/S Ratio (Annual)734.84x
Asset Turnover (Annual)0.01x
52-Week High$30.33
Operating Margin (5Y Avg)-1602.63%
EPS Excl Extra (Annual)$-0.24
CapEx CAGR (5Y)-1.26%
26-Week Price Return85.97%
Quick Ratio (Annual)33.47x
13-Week Price Return25.28%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)30.66x
Enterprise Value$19,871.095
Revenue / Share Growth (5Y)-16.50%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2346.02%
Cash / Share (Annual)$7.02
3-Month Return Std Dev54.34%
Gross Margin (5Y Avg)75.10%
Net Income / Employee (TTM)$-1
ROE (Last FY)-3.67%
Net Interest Coverage (Annual)-7.02x
EPS Basic Excl Extra (Annual)$-0.24
Receivables Turnover (TTM)4.67x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.17
Receivables Turnover (Annual)2.97x
ROI (TTM)-18.32%
P/S Ratio (TTM)1604.01x
Pretax Margin (5Y Avg)-1226.13%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$7.23
Price vs S&P 500 (52W)162.61%
Year-to-Date Return37.47%
5-Day Price Return3.04%
EPS Normalized (Annual)$-0.24
ROA (5Y Avg)-9.83%
Net Profit Margin (Annual)-591.96%
Month-to-Date Return7.69%
Cash Flow / Share (TTM)$-1.62
EBITD / Share (Annual)$-1.35
Operating Margin (Annual)-3442.63%
LT Debt / Equity (Annual)0.07x
ROI (5Y Avg)-17.22%
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$-1.17
P/TBV (Quarterly)1.51x
P/B Ratio (Annual)1.54x
Inventory Turnover (TTM)0.61x
Pretax Margin (TTM)-6925.09%
Book Value / Share (Annual)$6.74
Price vs S&P 500 (13W)22.42%
Beta1.19x
Revenue / Share (TTM)$0.02
ROE (TTM)-18.32%
52-Week Low$9.89
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.28
4.28
4.28
4.32
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ROIVRoivant Sciences Ltd. Common Shares | 1604.01x | -86.36% | 91.21% | — | $29.08 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Roivant Sciences is a commercial-stage biopharmaceutical company with VTAMA (tapinarof), an approved treatment for plaque psoriasis, as its lead marketed product. The company maintains a pipeline of drug candidates across development stages including Batoclimab, Brepocitinib, Namilumab, and IMVT-1402. Roivant also incubates discovery-stage biotech companies and health technology platforms adjacent to its core pharmaceutical business.